Consensus recommendations

Consensus recommendations

Grade

All individuals with cirrhosis should be enrolled in HCC screening programs.

A1

HCC surveillance should involve liver ultrasound + serum alpha-fetoprotein measurement performed every 6 months.

A1

All individuals with cirrhosis should be offered DAA treatment for HCV infection.

A1

HCC surveillance should continue long term after SVR in people with cirrhosis.

A1

Patients with HCC should be considered for DAA therapy.

A1

Decisions about the timing of DAA therapy for HCV in people with active HCC should be made with a multidisciplinary team.

B1

People with cirrhosis and prior HCC should be closely monitored for HCC recurrence during and after DAA therapy for HCV infection.

B2

HCC surveillance for all individuals with no cirrhosis is not cost-effective.

A1